IL231975A0 - Antibodies to cd1d - Google Patents
Antibodies to cd1dInfo
- Publication number
- IL231975A0 IL231975A0 IL231975A IL23197514A IL231975A0 IL 231975 A0 IL231975 A0 IL 231975A0 IL 231975 A IL231975 A IL 231975A IL 23197514 A IL23197514 A IL 23197514A IL 231975 A0 IL231975 A0 IL 231975A0
- Authority
- IL
- Israel
- Prior art keywords
- cd1d
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547307P | 2011-10-14 | 2011-10-14 | |
| AU2011904190A AU2011904190A0 (en) | 2011-10-14 | Antibodies to CD1d | |
| PCT/AU2012/001247 WO2013053021A1 (en) | 2011-10-14 | 2012-10-15 | ANTIBODIES TO CD1d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL231975A0 true IL231975A0 (en) | 2014-05-28 |
Family
ID=48081279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231975A IL231975A0 (en) | 2011-10-14 | 2014-04-07 | Antibodies to cd1d |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140286957A1 (enExample) |
| EP (1) | EP2766042A4 (enExample) |
| JP (1) | JP2015502915A (enExample) |
| KR (1) | KR20140108520A (enExample) |
| CN (1) | CN104144700B (enExample) |
| AU (1) | AU2012323781B8 (enExample) |
| BR (1) | BR112014008691A2 (enExample) |
| CA (1) | CA2850961A1 (enExample) |
| EA (1) | EA201400447A1 (enExample) |
| IL (1) | IL231975A0 (enExample) |
| MX (1) | MX2014004326A (enExample) |
| SG (1) | SG11201400521PA (enExample) |
| WO (1) | WO2013053021A1 (enExample) |
| ZA (1) | ZA201401776B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386714B (es) * | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| IL308831A (en) * | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| KR20190065189A (ko) * | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T 세포 수용체 |
| MX395611B (es) * | 2016-04-08 | 2025-03-25 | Adaptimmune Ltd | Receptores de celulas t. |
| CN108079292A (zh) * | 2016-11-23 | 2018-05-29 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |
| CN118662615A (zh) * | 2017-03-15 | 2024-09-20 | 浩康生物系统公司 | 用于造血干细胞移植的组合物和方法 |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
| AU2021328375A1 (en) * | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
| US20240050569A1 (en) * | 2020-12-18 | 2024-02-15 | Bioardis, Llc | Mesothelin binding molecules and uses thereof |
| WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
| CN116217704B (zh) * | 2022-10-25 | 2025-08-15 | 南京医科大学 | 一种抑制肝细胞凋亡的表面分子及其应用 |
| KR20250128342A (ko) * | 2022-12-21 | 2025-08-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 입양 면역요법을 위한 향상된 기능을 갖는 cd3 및 itcr을 발현하는 조작된 자연살해세포 |
| WO2024226794A1 (en) * | 2023-04-26 | 2024-10-31 | The Trustees Of Indiana University | Composition and methods for treatment of spinal cord injury and traumatic brain injury |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524146A (ja) * | 1998-07-09 | 2003-08-12 | ニッコロフ，ブライアン・ジェイ | Ｔ細胞上のナチュラルキラーレセプターとそれらに対応するリガンドとの相互作用を変調することにより疾患を治療する方法 |
| WO2003092615A2 (en) * | 2002-05-01 | 2003-11-13 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
| WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
| US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
-
2012
- 2012-10-15 SG SG11201400521PA patent/SG11201400521PA/en unknown
- 2012-10-15 EA EA201400447A patent/EA201400447A1/ru unknown
- 2012-10-15 CA CA2850961A patent/CA2850961A1/en not_active Abandoned
- 2012-10-15 WO PCT/AU2012/001247 patent/WO2013053021A1/en not_active Ceased
- 2012-10-15 MX MX2014004326A patent/MX2014004326A/es unknown
- 2012-10-15 CN CN201280050432.2A patent/CN104144700B/zh not_active Expired - Fee Related
- 2012-10-15 AU AU2012323781A patent/AU2012323781B8/en not_active Ceased
- 2012-10-15 BR BR112014008691A patent/BR112014008691A2/pt unknown
- 2012-10-15 EP EP12840164.3A patent/EP2766042A4/en not_active Withdrawn
- 2012-10-15 JP JP2014534890A patent/JP2015502915A/ja active Pending
- 2012-10-15 KR KR1020147012848A patent/KR20140108520A/ko not_active Withdrawn
-
2014
- 2014-03-11 ZA ZA2014/01776A patent/ZA201401776B/en unknown
- 2014-04-07 IL IL231975A patent/IL231975A0/en unknown
- 2014-04-10 US US14/249,566 patent/US20140286957A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012323781A1 (en) | 2014-03-27 |
| EA201400447A1 (ru) | 2014-09-30 |
| EP2766042A4 (en) | 2015-05-27 |
| US20140286957A1 (en) | 2014-09-25 |
| ZA201401776B (en) | 2016-01-27 |
| CA2850961A1 (en) | 2013-04-18 |
| CN104144700B (zh) | 2016-10-19 |
| WO2013053021A1 (en) | 2013-04-18 |
| KR20140108520A (ko) | 2014-09-11 |
| AU2012323781A8 (en) | 2015-05-14 |
| AU2012323781B2 (en) | 2015-04-23 |
| JP2015502915A (ja) | 2015-01-29 |
| SG11201400521PA (en) | 2014-08-28 |
| AU2012323781B8 (en) | 2015-05-14 |
| BR112014008691A2 (pt) | 2017-06-13 |
| NZ622050A (en) | 2016-07-29 |
| MX2014004326A (es) | 2014-09-25 |
| CN104144700A (zh) | 2014-11-12 |
| EP2766042A1 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272035A (en) | Anti IL–36R antibodies | |
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| ZA201307983B (en) | Anti-b7-h3 antibody | |
| IL228001A0 (en) | Antibodies to 70cd | |
| ZA201401776B (en) | Antibodies to cd1d | |
| IL229254A0 (en) | Therapeutic antibodies | |
| IL230719A0 (en) | highly galactosylated antibodies | |
| IL232017A0 (en) | Antibodies of human origin to inkt | |
| EP2764325A4 (en) | USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| GB201121564D0 (en) | Use of antibody | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| PT2751094T (pt) | Nova forma de cristal | |
| EP2719842A4 (en) | REINFORCING FOR STRUCTURAL USE | |
| AU2011904190A0 (en) | Antibodies to CD1d | |
| GB201116456D0 (en) | Improvements relating to foorwear | |
| GB201100188D0 (en) | Structural members | |
| HUE041625T2 (hu) | Terápiás ellenanyagok |